Pipeline!, Pipeline!, Pipeline! (The future of telomeres in medicine)
In real estate it is location, location, location. In the pharmaceutical industry it is all about the pipeline. If Imetelstat works in one situation, it will likely work in others, alone or in combination. This potential makes this telomere development extremely promising and valuable. Some believe that telomere control will lead to major medical breakthroughs. Celgene and JNJ have shown interest in this research.
The potential has been proven. The Nobel Prize winning telomeres and new science have been proven. The interest from other "deep pocket" drug companies is a fact. This will be a continuing area of research for a very long time. My "bet" is that there will be notable medicines that will now (Imetelstat), and over the years, will fill an unmet need.
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Imetelstat (GRN163L) is a potent and specific inhibitor of telomerase. This first-in-class compound is a specially designed and modified short oligonucleotide, which targets and binds directly with high affinity to the active site of telomerase. Unique and proprietary oligonucleotide chemistry improves binding affinity and stability in plasma and tissues. A lipid modification enables cellular and tissue penetration and biodistribution.
Based on data from the trial of imetelstat in patients with ET, in November 2012, Dr. Ayalew Tefferi at Mayo Clinic initiated an investigator-sponsored trial to evaluate the safety and efficacy of imetelstat in patients with MF and to determine an appropriate dose and schedule for further evaluation.
Dr. Tefferi has communicated to Geron that enrollment of the first cohort of 11 patients in the study was completed at the end of March 2013 and that the pre-specified criteria in the clinical protocol of at least two responders with a clinical improvement (CI), partial remission (PR) or complete remission (CR) according to the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria in the first 11 patients was met to enable expanded enrollment. In the first cohort of 11 patients with MF, imetelstat was administered once every three weeks. In the second cohort of an additional 11 patients with MF, imetelstat initially will be administered weekly during a four week induction phase, followed by a maintenance regimen in which imetelstat is given once every three weeks. Geron expects data from the investigator-sponsored trial, if positive, to inform the design of a company-sponsored multi-center trial in MF.
Geron also intends to expand its directed program of investigator-sponsored trials in 2013 to other hematologic
NEW YORK (AP) - Three Americans won the Nobel prize in medicine for discovering how chromosomes protect themselves as cells divide, work that has inspired experimental cancer therapies and may offer insights into aging.
The research by Elizabeth H. Blackburn, Carol W. Greider and Jack W. Szostak revealed the workings of chromosome features called telomeres, which play an important role in the aging of cells.
It's the first time two women have shared in a single Nobel science prize. Over the years, a total of 10 women have won the prize in medicine.
Blackburn, 60, who holds U.S. and Australian citizenship, is a professor of biology and physiology at the University of California, San Francisco. Greider, 48, is a professor in the department of molecular biology and genetics at Johns Hopkins University School of Medicine in Baltimore.
London-born Szostak, 56, is a professor of genetics at Harvard Medical School and a researcher with the Howard Hughes Medical Institute.
Their work, done in the 1970s and 1980s, showed how features at the tips of chromosomes - telomeres (TEE-loh-meers) - can keep them from getting progressively shorter as cells divide. It's been compared to the way plastic tips on the ends of shoelaces keep the laces from fraying.
Blackburn and Greider discovered an enzyme, telomerase (teh-LAH-meh-race), that maintains the lengths of the telomeres. Later research has shown that telomerase is switched on in almost all cancers.
Telomerase is active before birth, when cells are dividing rapidly. By age 4 or 5 it's basically shut off in almost all cells. That means the telomeres degrade over time, leading those cells to age and eventually stop dividing. But scientists have shown that adding telomerase to human cells can extend their lifespan indefinitely.
Such research spurred speculation that telomerase might turn out to be a fountain of youth. But experts say that aging is more complicated than just changes in telomeres. Scientists are still studying what impact telomeres might have; perhaps they will reveal ways to ward off some aspects of aging, researchers say.
Still other work showed that telomerase helps cancer cells sustain their uncontrolled growth. Scientists are trying to exploit that to produce new therapies, noted Jerry Shay of the University of Texas Southwestern Medical Center in Dallas.
Anyone waiting on a "phase 3, regarding anything Geron, will be waiting a long, long, time. The "fringe lunatics" on this forum have extremely short memories. Remember the euphoria created by GERN's last march to $2.99?........and the terrible disappointment when investors were informed about the failures of GRN 1005 in brain tumors?......and the failure of Imetelstat in breast cancer?
Well, THIS "fringe lunatic" will not count his Imetelstat chickens anymore until the hatching process has occurred and a product is brought to market.......and I start either getting profit checks from sales of my stock....or I receive a profit from the sale of the company.